References
- Agid Y., Javoy‐Agid F. Neuropeptides in Parkinson disease. Trends in Neuroscience 1985; 8: 30–35
- Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Mynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathologica (Berlin) 1983; 61: 101–108
- Bakay L. The blood‐brain barrier. Charles C. Thomas, Springfield, IL 1956
- Barbeau A. Role of peptides in the pathogenesis and treatment of Parkinson's disease. Central nervous system effects of hypothalamic hormones and other peptides, A. Coll. Raven Press, New York 1979; 403–414
- Boller F., Mizutani T., Roessmann U., Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Annals of Neurology 1980; 7: 329–335
- Cuello A. C. Central distribution of opioid peptides. British Medical Bulletin 1983; 39: 11–16
- Ditter S. M., Mirra S. Parkinson's disease features in Alzheimer's disease: a neuropathologic and clinical study. Neurology 1986; 36(Suppl. 1)225
- Haklim A. M., Mathieson G. Dementia in Parkinson's disease: a neuropathologic study. Neurology 1979; 29: 1209–1214
- Hirano A., Zimmerman H. M. Alzheimer‐ neurofibrillary changes. A topographic study. Archives of Neurology 1962; 7: 227–242
- Huber S. J., Shuttleworth E. C., Paulson G. W., Bullchamber Mj. G., Clapp L. E. Cortical vs. subcortical dementia: neuropsychological differences. Archives of Neurology 1986; 43: 392–394
- Iacono R. P., Sandyk K. Non‐cholinergic mechanisms in Alzheimer's disease. Annals of Neurology
- Javoy‐Agid F., Ruberg M., Hirsch E., Cash R., Raisman R., Taquet H., Epelbaum J., Scatton B., Duyckaerts C., Agid Y. Recent progress in the neurochemistry of Parkinson's disease. Recent developments in Parkinson's disease, S. Fahn. Raven Press, New York 1986; 67–83
- Kaiya H., Tanaka T., Takeuchi K., Morita K., Adachi S., Shirakawa H., Ueki H., Namba M. Decreased level of beta‐endorphin‐like immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Life Sciences 1983; 33: 1039–1043
- Moroni F., Cheney D. L., Costa E. Beta‐endorphin inhibits ACh turnover in nuclei of rat brain. Nature 1977; 267: 267–268
- Nandy K. Brain‐reactive antibodies in serum of aged mice. Neurobiological aspects of maturation and aging, D. H. Ford. Elsevier, Amsterdam 1973; 437–154
- Nappi G., Ptraglia F., Martignoni E., Facchinetti F., Bono G., Genazzani A. R. Beta‐ endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 1985; 35: 1371–1374
- Van Loon G. R., Kim C. Beta‐endorphin‐induced increase in striatal dopamine turnover. Life Sciences 1978; 23: 961–970
- Versteeg D. H. G., De Crom M. P. G., Mulder A. H. ACTH‐ (1–24) and alpha‐MSH antagonize dopamine receptor‐mediated inhibition of striatal dopamine and acetylcholine release. Life Sciences 1986; 38: 835–840
- Whitehouse P. J., Martino A. M., Marcus K., Mayeux R., Davis L. E., Price D. L., Kellar K. J. Reductions in cortical nicotinic receptors in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. Neurology 1986; 36(Suppl. 1)224